Literature DB >> 21048032

The European LeukemiaNet: achievements and perspectives.

Rüdiger Hehlmann1, David Grimwade, Bengt Simonsson, Jane Apperley, Michele Baccarani, Tiziano Barbui, Giovanni Barosi, Renato Bassan, Marie C Béné, Ute Berger, Thomas Büchner, Alan Burnett, Nicolas C P Cross, Theo J M de Witte, Hartmut Döhner, Hervé Dombret, Hermann Einsele, Georg Engelich, Robin Foà, Christa Fonatsch, Nicola Gökbuget, Elaine Gluckman, Alois Gratwohl, Francois Guilhot, Claudia Haferlach, Thorsten Haferlach, Michael Hallek, Jörg Hasford, Andreas Hochhaus, Dieter Hoelzer, Jean-Jaques Kiladjian, Boris Labar, Per Ljungman, Ulrich Mansmann, Dietger Niederwieser, Gert Ossenkoppele, José M Ribera, Harald Rieder, Hubert Serve, Petra Schrotz-King, Miguel A Sanz, Susanne Saussele.   

Abstract

The only way to cure leukemia is by cooperative research. To optimize research, the European LeukemiaNet integrates 105 national leukemia trial groups and networks, 105 interdisciplinary partner groups and about 1,000 leukemia specialists from 175 institutions. They care for tens of thousands of leukemia patients in 33 countries across Europe. Their ultimate goal is to cure leukemia. Since its inception in 2002, the European LeukemiaNet has steadily expanded and has unified leukemia research across Europe. The European LeukemiaNet grew from two major roots: 1) the German Competence Network on Acute and Chronic Leukemias; and 2) the collaboration of European Investigators on Chronic Myeloid Leukemia. The European LeukemiaNet has improved leukemia research and management across Europe. Its concept has led to funding by the European Commission as a network of excellence. Other sources (European Science Foundation; European LeukemiaNet-Foundation) will take over when the support of the European Commission ends.

Entities:  

Mesh:

Year:  2010        PMID: 21048032      PMCID: PMC3012780          DOI: 10.3324/haematol.2010.032979

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  40 in total

1.  The German competence network 'Acute and chronic leukemias'.

Authors:  R Hehlmann; U Berger; C Aul; Th Büchner; H Döhner; G Ehninger; A Ganser; N Gökbuget; D Hoelzer; K Uberla; W Gassmann; W D Ludwig; H Rieder; M Kneba; A Hochhaus; A Reiter; W Hiddemann; O G Ottmann; U Germing; K Adelhard; M Dugas; P Dirschedl; D Messerer; A Böhme; E Harrison-Neu; M Griesshammer; J Kienast; H J Kolb; A D Ho; M Hallek; A Neubauer; B Schlegelberger; D Niederwieser; G Heil; T Müller; J Hasford
Journal:  Leukemia       Date:  2004-04       Impact factor: 11.528

2.  JAK2V617F mutation persists in blasts and mature cells of transformed JAK2V617F-positive-myeloproliferative neoplasia: a European Leukemia Net (ENL) study.

Authors:  Ciro R Rinaldi; Paola Rinaldi; Marica Gemei; Francesco Grimaldi; Giorgia Battipaglia; Luigi Del Vecchio; Bruno Martino; Giorgina Specchia; Anna Candoni; Luigi Gugliotta; Alessandro M Vannucchi; Tiziano Barbui; Fabrizio Pane
Journal:  Am J Hematol       Date:  2010-05       Impact factor: 10.047

3.  Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT.

Authors:  P Ljungman; D Engelhard; R de la Cámara; H Einsele; A Locasciulli; R Martino; P Ribaud; K Ward; C Cordonnier
Journal:  Bone Marrow Transplant       Date:  2005-04       Impact factor: 5.483

4.  Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria.

Authors:  Alessandra Carobbio; Guido Finazzi; Elisabetta Antonioli; Alessandro M Vannucchi; Giovanni Barosi; Marco Ruggeri; Francesco Rodeghiero; Federica Delaini; Alessandro Rambaldi; Tiziano Barbui
Journal:  Blood       Date:  2010-05-17       Impact factor: 22.113

Review 5.  A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process.

Authors:  Giovanni Barosi; Gunnar Birgegard; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Hasselbalch; Jean-Jacques Kiladijan; Eva Lengfelder; Ruben Mesa; Mary F Mc Mullin; Francesco Passamonti; John T Reilly; Alessandro M Vannucchi; Tiziano Barbui
Journal:  Br J Haematol       Date:  2009-11-23       Impact factor: 6.998

6.  The role of stem cell source in autologous hematopoietic stem cell transplantation for patients with myelodysplastic syndromes.

Authors:  Theo de Witte; Ronald Brand; Anja van Biezen; Michel Delforge; Harold Biersack; Reuven Or; Giovanna Meloni; Beppe Bandini; Jorge Sierra; Nicolaus Kroger; Alois Gratwohl; Dietger Niederwieser
Journal:  Haematologica       Date:  2006-06       Impact factor: 9.941

7.  Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group.

Authors:  Torsten Haferlach; Alexander Kohlmann; Lothar Wieczorek; Giuseppe Basso; Geertruy Te Kronnie; Marie-Christine Béné; John De Vos; Jesus M Hernández; Wolf-Karsten Hofmann; Ken I Mills; Amanda Gilkes; Sabina Chiaretti; Sheila A Shurtleff; Thomas J Kipps; Laura Z Rassenti; Allen E Yeoh; Peter R Papenhausen; Wei-Min Liu; P Mickey Williams; Robin Foà
Journal:  J Clin Oncol       Date:  2010-04-20       Impact factor: 44.544

Review 8.  Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

Authors:  Hartmut Döhner; Elihu H Estey; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Alan K Burnett; Hervé Dombret; Pierre Fenaux; David Grimwade; Richard A Larson; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel A Sanz; Jorge Sierra; Martin S Tallman; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

9.  Four- and five-color flow cytometry analysis of leukocyte differentiation pathways in normal bone marrow: a reference document based on a systematic approach by the GTLLF and GEIL.

Authors:  Christine Arnoulet; Marie C Béné; Françoise Durrieu; Jean Feuillard; Chantal Fossat; Bernard Husson; Hélène Jouault; Marc Maynadié; Francis Lacombe
Journal:  Cytometry B Clin Cytom       Date:  2010-01       Impact factor: 3.058

Review 10.  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.

Authors:  Timothy Hughes; Michael Deininger; Andreas Hochhaus; Susan Branford; Jerald Radich; Jaspal Kaeda; Michele Baccarani; Jorge Cortes; Nicholas C P Cross; Brian J Druker; Jean Gabert; David Grimwade; Rüdiger Hehlmann; Suzanne Kamel-Reid; Jeffrey H Lipton; Janina Longtine; Giovanni Martinelli; Giuseppe Saglio; Simona Soverini; Wendy Stock; John M Goldman
Journal:  Blood       Date:  2006-03-07       Impact factor: 22.113

View more
  7 in total

1.  New opportunities and new problems for acute myeloid leukemia treatment.

Authors:  Idoya Lahortiga; Jan Cools
Journal:  Haematologica       Date:  2012-06       Impact factor: 9.941

2.  Value of multifaced approach diagnosis and classification of acute leukemias.

Authors:  Silvana Angelescu; Nicoleta Mariana Berbec; Andrei Colita; Doina Barbu; Anca Roxana Lupu
Journal:  Maedica (Buchar)       Date:  2012-09

3.  The European Hematology Association Roadmap for European Hematology Research: a consensus document.

Authors:  Andreas Engert; Carlo Balduini; Anneke Brand; Bertrand Coiffier; Catherine Cordonnier; Hartmut Döhner; Thom Duyvené de Wit; Sabine Eichinger; Willem Fibbe; Tony Green; Fleur de Haas; Achille Iolascon; Thierry Jaffredo; Francesco Rodeghiero; Gilles Salles; Jan Jacob Schuringa
Journal:  Haematologica       Date:  2016-01-27       Impact factor: 9.941

4.  A prospective registration study to determine feasibility of hematopoietic SCT in adults with acute leukemia: planning, expectations and reality.

Authors:  M Labopin; N-C Gorin; E Polge; G Socié; G Gurman; E Gluckman; P Jindra; X Poiré; K Schäfer-Eckart; T Ruutu; G Milone; W Arcese; M Mohty; V Rocha
Journal:  Bone Marrow Transplant       Date:  2013-11-18       Impact factor: 5.483

Review 5.  Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.

Authors:  N C P Cross; H E White; D Colomer; H Ehrencrona; L Foroni; E Gottardi; T Lange; T Lion; K Machova Polakova; S Dulucq; G Martinelli; E Oppliger Leibundgut; N Pallisgaard; G Barbany; T Sacha; R Talmaci; B Izzo; G Saglio; F Pane; M C Müller; A Hochhaus
Journal:  Leukemia       Date:  2015-02-05       Impact factor: 11.528

6.  Differential Analysis of Genetic, Epigenetic, and Cytogenetic Abnormalities in AML.

Authors:  Mirazul Islam; Zahurin Mohamed; Yassen Assenov
Journal:  Int J Genomics       Date:  2017-06-20       Impact factor: 2.326

7.  Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.

Authors:  Luca Malcovati; Eva Hellström-Lindberg; David Bowen; Lionel Adès; Jaroslav Cermak; Consuelo Del Cañizo; Matteo G Della Porta; Pierre Fenaux; Norbert Gattermann; Ulrich Germing; Joop H Jansen; Moshe Mittelman; Ghulam Mufti; Uwe Platzbecker; Guillermo F Sanz; Dominik Selleslag; Mette Skov-Holm; Reinhard Stauder; Argiris Symeonidis; Arjan A van de Loosdrecht; Theo de Witte; Mario Cazzola
Journal:  Blood       Date:  2013-08-26       Impact factor: 22.113

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.